Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

• Published in: Blood Vol. 128; no. 8; pp. 1112 - 1120
• Main Authors: Jurinovic, Vindi, Kridel, Robert, Staiger, Annette M., Szczepanowski, Monika, Horn, Heike, Dreyling, Martin H., Rosenwald, Andreas, Ott, German, Klapper, Wolfram, Zelenetz, Andrew D., Barr, Paul M., Friedberg, Jonathan W., Ansell, Stephen, Sehn, Laurie H., Connors, Joseph M., Gascoyne, Randy D., Hiddemann, Wolfgang, Unterhalt, Michael, Weinstock, David M., Weigert, Oliver
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 25.08.2016; American Society of Hematology
• Subjects: Adult; Aged; Disease Progression; Disease-Free Survival; Female; Humans; Immunotherapy; Lymphoid Neoplasia; Lymphoma, Follicular - drug therapy; Lymphoma, Follicular - immunology; Lymphoma, Follicular - pathology; Male; Middle Aged; Models, Biological; Reproducibility of Results; Risk Factors; Survival Analysis
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2016-05-717355

Follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. Posttreatment surrogate end points, such as progression of disease within 24 months (POD24) are promising predictors for overall survival (OS) but are of limited clinical value, primarily because they cannot guide up-front treatment decisions. We used the clinical and molecular data from 2 independent cohorts of symptomatic patients in need of first-line immunochemotherapy (151 patients from a German Low-Grade Lymphoma Study Group [GLSG] trial and 107 patients from a population-based registry of the British Columbia Cancer Agency [BCCA]) to validate the predictive utility of POD24, and to evaluate the ability of pretreatment risk models to predict early treatment failure. POD24 occurred in 17% and 23% of evaluable GLSG and BCCA patients, with 5-year OS rates of 41% (vs 91% for those without POD24, P < .0001) and 26% (vs 86%, P < .0001), respectively. The m7–FL International Prognostic Index (m7-FLIPI), a prospective clinicogenetic risk model for failure-free survival, had the highest accuracy to predict POD24 (76% and 77%, respectively) with an odds ratio of 5.82 in GLSG (P = .00031) and 4.76 in BCCA patients (P = .0052). A clinicogenetic risk model specifically designed to predict POD24, the POD24-PI, had the highest sensitivity to predict POD24, but at the expense of a lower specificity. In conclusion, the m7-FLIPI prospectively identifies the smallest subgroup of patients (28% and 22%, respectively) at highest risk of early failure of first-line immunochemotherapy and death, including patients not fulfilling the POD24 criteria, and should be evaluated in prospective trials of precision medicine approaches in FL. •The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS.•A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.